These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30718500)

  • 1. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis.
    Wang G; Zhang X; Cheng W; Mo Y; Chen J; Cao Z; Chen X; Cui H; Liu S; Huang L; Liu M; Ma L; Ma NF
    Cell Death Dis; 2021 Sep; 12(10):891. PubMed ID: 34588420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.
    Xiao L; Lan X; Shi X; Zhao K; Wang D; Wang X; Li F; Huang H; Liu J
    Cell Death Dis; 2017 May; 8(5):e2803. PubMed ID: 28518145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
    Tian R; Zhang C; Xiong F; Chen H
    Front Biosci (Landmark Ed); 2020 Mar; 25(5):948-960. PubMed ID: 32114419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
    Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
    Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
    Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
    Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling.
    Vesel M; Rapp J; Feller D; Kiss E; Jaromi L; Meggyes M; Miskei G; Duga B; Smuk G; Laszlo T; Karner I; Pongracz JE
    Respir Res; 2017 Mar; 18(1):52. PubMed ID: 28340578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
    Zhang S; Wang Y
    J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
    Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H
    Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
    Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
    Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
    Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
    Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human RECQL5 promotes metastasis and resistance to cisplatin in non-small cell lung cancer.
    Xia HW; Zhang ZQ; Yuan J; Niu QL
    Life Sci; 2021 Jan; 265():118768. PubMed ID: 33217443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer.
    Li LB; Yang LX; Liu L; Liu FR; Li AH; Zhu YL; Wen H; Xue X; Tian ZX; Sun H; Li PC; Zhao XG
    Acta Pharmacol Sin; 2024 May; 45(5):1060-1076. PubMed ID: 38228910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.
    Fayi MA; Alamri A; Rajagopalan P
    Oncol Res; 2020 Mar; 28(2):177-189. PubMed ID: 31771696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.